Revolutionizing Heart Monitoring for AFib Patients
Cardea Sciences is developing a non-invasive heart monitoring device to improve early detection, treatment outcomes, and quality of life for Atrial Fibrillation patients.
In Collaboration With
About Cardea Science
Cardea Sciences, founded in 2016 by Dr. Ya-El Mandel-Portnoy, is a health tech innovator based in New York City. We’re on a mission to transform how Atrial Fibrillation (AFib) is monitored and managed through cutting-edge, non-invasive technology.
Our Benefits
Early AFib Detection
Physician Insights
Better Patient Outcomes
The Problem We Solve
Atrial Fibrillation affects millions globally, yet not all patients experience the same symptoms or risks. Cardea’s novel metric helps identify which patients will struggle with arrhythmia before serious adverse events occur — enabling earlier, more effective intervention.
Our Solution
- Real-time objective data
- Insights on individual tolerance to AFib
- Clinician-ready reports for actionable care
Meet The Founder
Founder & CEO
Ya-El Mandel-Portnoy
R&D Director
Gregor Schwartz
Contact
Cardea Science, Inc. New York, NY, United States info@cardeascience.com
Cardea Science
Advancing non-invasive heart monitoring for a healthier future. Join us in redefining how Atrial Fibrillation is detected and treated.
Learn more about Us
© 2025 Cardea Science. All rights reserved. Privacy Policy | Terms of Service